Bray Capital Advisors Has $2.86 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Bray Capital Advisors decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 21.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 19,796 shares of the company's stock after selling 5,368 shares during the period. Bray Capital Advisors' holdings in Johnson & Johnson were worth $2,863,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Janus Henderson Group PLC boosted its stake in Johnson & Johnson by 228.1% in the 3rd quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company's stock worth $549,223,000 after purchasing an additional 2,356,359 shares during the period. Franklin Resources Inc. boosted its stake in Johnson & Johnson by 11.4% in the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock worth $2,721,355,000 after purchasing an additional 1,729,281 shares during the period. Holocene Advisors LP acquired a new position in Johnson & Johnson in the 3rd quarter worth $225,040,000. FMR LLC boosted its stake in Johnson & Johnson by 7.4% in the 3rd quarter. FMR LLC now owns 18,316,920 shares of the company's stock worth $2,968,440,000 after purchasing an additional 1,265,748 shares during the period. Finally, State Street Corp boosted its stake in Johnson & Johnson by 0.9% in the 3rd quarter. State Street Corp now owns 134,245,811 shares of the company's stock worth $21,755,874,000 after purchasing an additional 1,154,088 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the firm's stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on JNJ. Wells Fargo & Company reduced their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Raymond James reduced their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Bank of America reduced their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, January 23rd. Royal Bank of Canada reissued an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Finally, Citigroup cut their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $170.67.

Johnson & Johnson Stock Up 1.7 %

Shares of JNJ stock opened at $162.35 on Monday. The stock has a market cap of $390.87 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The firm's 50-day moving average is $148.93 and its 200-day moving average is $155.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business's revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.29 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.06%. Johnson & Johnson's dividend payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.